{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:15:06Z","timestamp":1791299706158,"version":"4.1.0"},"reference-count":173,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1053\/j.semnuclmed.2016.09.005","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T06:31:48Z","timestamp":1480055508000},"page":"31-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Clinical Amyloid Imaging"],"prefix":"10.1053","volume":"47","author":[{"given":"Atul","family":"Mallik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Minoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2016.09.005_bib1","unstructured":"Murphy SL Jiaquan Xu, Kochanek KD. Deaths: Final data for 2010. in National Vital Statistics Reports, (ed). vol 61. Hyattsville, MD: National Center for Health Statistics, 2013"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: A systematic review and meta-analysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJMe1313943","article-title":"Antiamyloid therapy for Alzheimer\u2019s disease\u2014Are we on the right road?","volume":"370","author":"Karran","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.arr.2016.01.005","article-title":"Amyloid imaging: Past, present and future perspectives","volume":"30","author":"Villemagne","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"338","key":"10.1053\/j.semnuclmed.2016.09.005_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.arr.2015.12.010","article-title":"Advances in the development of tau PET radiotracers and their clinical applications","volume":"30","author":"Okamura","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"44","key":"10.1053\/j.semnuclmed.2016.09.005_bib8","doi-asserted-by":"crossref","first-page":"29615","DOI":"10.1074\/jbc.R800019200","article-title":"Amyloid precursor protein trafficking, processing, and function","volume":"283","author":"Thinakaran","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer\u2019s disease","volume":"34","author":"O\u2019Brien","year":"2011","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","article-title":"Soluble pool of A\u03b2 amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease","volume":"46","author":"McLean","year":"1999","journal-title":"Ann Neurol"},{"issue":"14","key":"10.1053\/j.semnuclmed.2016.09.005_bib11","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7512","key":"10.1053\/j.semnuclmed.2016.09.005_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/512032a","article-title":"Neurodegeneration: Alzheimer\u2019s disease under strain","volume":"512","author":"Aguzzi","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000100355","article-title":"Amyloid-beta aggregation","volume":"4","author":"Finder","year":"2007","journal-title":"Neurodegener Dis"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1750-3639.1991.tb00661.x","article-title":"Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections","volume":"1","author":"Braak","year":"1991","journal-title":"Brain Pathol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/nen.0b013e31815c5efb","article-title":"Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles \u201cdo count\u201d when staging disease severity","volume":"66","author":"Nelson","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00005072-199902000-00010","article-title":"Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of A\u03b2","volume":"58","author":"Thal","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.09.005_bib17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","article-title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging","volume":"67","author":"Morris","year":"2010","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1053\/j.semnuclmed.2016.09.005_bib19","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"J Am Med Assoc"},{"issue":"2\u20133","key":"10.1053\/j.semnuclmed.2016.09.005_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000354670","article-title":"The significance of alpha-synuclein, amyloid-beta and tau pathologies in Parkinson\u2019s disease progression and related dementia","volume":"13","author":"Compta","year":"2014","journal-title":"Neurodegener Dis"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.09.005_bib21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.26191","article-title":"Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: A systematic review","volume":"30","author":"Petrou","year":"2015","journal-title":"Mov Disord"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.20819","article-title":"Interface between tauopathies and synucleinopathies: A tale of two proteins","volume":"59","author":"Galpern","year":"2006","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","article-title":"Amyloid load in Parkinson\u2019s disease dementia and Lewy body dementia measured with 11C-PIB positron emission tomography","volume":"79","author":"Edison","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.21164","article-title":"Imaging of amyloid burden and distribution in cerebral amyloid angiopathy","volume":"62","author":"Johnson","year":"2007","journal-title":"Ann Neurol"},{"issue":"5054","key":"10.1053\/j.semnuclmed.2016.09.005_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2012.03.002","article-title":"Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer\u2019s parents","volume":"34","author":"Mosconi","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.09.005_bib27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ana.23665","article-title":"Effect of lifestyle activities on Alzheimer disease biomarkers and cognition","volume":"72","author":"Vemuri","year":"2012","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.21212","article-title":"Cognitive reserve hypothesis: Pittsburgh compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer\u2019s disease","volume":"63","author":"Kemppainen","year":"2008","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib29","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.09.005_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0306-4522(02)00907-7","article-title":"In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer\u2019s brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-18F-fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile","volume":"117","author":"Agdeppa","year":"2003","journal-title":"Neuroscience"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.09.005_bib33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.nucmedbio.2012.03.001","article-title":"In vitro characterization of 18F-florbetaben, an A\u03b2 imaging radiotracer","volume":"39","author":"Fodero-Tavoletti","year":"2012","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib34","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1471-4159.2008.05245.x","article-title":"In vitro high affinity \u03b1-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain","volume":"105","author":"Ye","year":"2008","journal-title":"J Neurochem"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography \u03b2-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.09.005_bib37","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","article-title":"Amyloid PET imaging in Alzheimer\u2019s disease: A comparison of three radiotracers","volume":"41","author":"Landau","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","article-title":"Comparison of 11C-PIB and 18F-florbetaben for A\u03b2 imaging in ageing and Alzheimer\u2019s disease","volume":"39","author":"Villemagne","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnumed.112.109009","article-title":"Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods","volume":"54","author":"Landau","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.111.094029","article-title":"Clinical validation of 18F-AZD4694, an amyloid-\u03b2-specific PET radioligand","volume":"53","author":"Cselenyi","year":"2012","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1148\/radiology.150.3.6607481","article-title":"Imaging local brain function with emission computed tomography","volume":"150","author":"Kuhl","year":"1984","journal-title":"Radiology"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.09.005_bib44","first-page":"1238","article-title":"A diagnostic approach in Alzheimer\u2019s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET","volume":"36","author":"Minoshima","year":"1995","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ana.410420114","article-title":"Metabolic reduction in the posterior cingulate cortex in very early Alzheimer\u2019s disease","volume":"42","author":"Minoshima","year":"1997","journal-title":"Ann Neurol"},{"issue":"13","key":"10.1053\/j.semnuclmed.2016.09.005_bib46","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1212\/WNL.0b013e31826c1be1","article-title":"FDG-PET and molecular brain imaging in the movement disorders clinic","volume":"79","author":"Bohnen","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib47","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1148\/rg.343135065","article-title":"Brain PET in suspected dementia: Patterns of altered FDG metabolism","volume":"34","author":"Brown","year":"2014","journal-title":"Radiographics"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.09.005_bib48","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/01.wnl.0000269790.05105.16","article-title":"What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?","volume":"69","author":"Jagust","year":"2007","journal-title":"Neurology"},{"issue":"17","key":"10.1053\/j.semnuclmed.2016.09.005_bib49","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","article-title":"Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome","volume":"286","author":"Silverman","year":"2001","journal-title":"J Am Med Assoc"},{"issue":"13","key":"10.1053\/j.semnuclmed.2016.09.005_bib50","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1212\/WNL.0b013e31826c1b0a","article-title":"18F-FDG-PET is superior to 123I-IBZM-SPECT for the differential diagnosis of parkinsonism","volume":"79","author":"Hellwig","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.neuroimage.2007.09.020","article-title":"Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer\u2019s disease","volume":"39","author":"Drzezga","year":"2008","journal-title":"Neuroimage"},{"issue":"15","key":"10.1053\/j.semnuclmed.2016.09.005_bib52","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1212\/01.wnl.0000259035.98480.ed","article-title":"11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration","volume":"68","author":"Rabinovici","year":"2007","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2377-9-41","article-title":"Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: A prospective, community-based study","volume":"9","author":"Panegyres","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib54","doi-asserted-by":"crossref","first-page":"216A","DOI":"10.1097\/00002826-199201001-00113","article-title":"Pharmacological challenge and PET imaging","volume":"15","author":"Dolan","year":"1992","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pscychresns.2007.12.006","article-title":"Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder","volume":"164","author":"Rasgon","year":"2008","journal-title":"Psychiatry Res"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.09.005_bib56","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib57","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00401-012-0943-2","article-title":"Early AD pathology in a [C-11]PiB-negative case: A PiB-amyloid imaging, biochemical, and immunohistochemical study","volume":"123","author":"Ikonomovic","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archneurol.2010.357","article-title":"In vivo fibrillar beta-amyloid detected using 11C-PiB positron emission tomography and neuropathologic assessment in older adults","volume":"68","author":"Sojkova","year":"2011","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.0b013e3181c7da8e","article-title":"In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia","volume":"74","author":"Burack","year":"2010","journal-title":"Neurology"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib60","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archneurol.2009.279","article-title":"Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: A case report","volume":"66","author":"Cairns","year":"2009","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.09.005_bib61","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/jnnp.2008.171496","article-title":"11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease","volume":"80","author":"Villemagne","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 6","key":"10.1053\/j.semnuclmed.2016.09.005_bib62","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archneur.64.3.431","article-title":"Molecular imaging with Pittsburgh compound B confirmed at autopsy: A case report","volume":"64","author":"Bacskai","year":"2007","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib64","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1474-4422(15)00093-9","article-title":"Multimodal imaging in Alzheimer\u2019s disease: Validity and usefulness for early detection","volume":"14","author":"Teipel","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib65","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-140162","article-title":"Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions","volume":"42","author":"Serrano","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib67","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00401-012-1051-z","article-title":"18F-flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: Pooled analysis of four studies","volume":"124","author":"Rinne","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.09.005_bib68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.09.005_bib69","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archneurol.2011.535","article-title":"Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease","volume":"68","author":"Sabbagh","year":"2011","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib70","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00401-012-1025-1","article-title":"Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques","volume":"124","author":"Driscoll","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"Pt 1","key":"10.1053\/j.semnuclmed.2016.09.005_bib71","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/brain\/awq349","article-title":"Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh compound B positron emission tomography patient with Alzheimer\u2019s disease","volume":"134","author":"Kadir","year":"2011","journal-title":"Brain"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib72","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archneur.65.10.noc80013","article-title":"Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B","volume":"65","author":"Leinonen","year":"2008","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib73","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JAD-132561","article-title":"Concordance between cerebrospinal fluid biomarkers and 11C-PIB PET in a memory clinic cohort","volume":"41","author":"Zwan","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.09.005_bib74","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.neurobiolaging.2011.10.001","article-title":"Cerebrovascular disease, beta-amyloid, and cognition in aging","volume":"33","author":"Marchant","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib76","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","article-title":"Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by 11C-PiB","volume":"74","author":"Resnick","year":"2010","journal-title":"Neurology"},{"issue":"19","key":"10.1053\/j.semnuclmed.2016.09.005_bib78","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","article-title":"Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later","volume":"80","author":"Roe","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib79","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archneur.58.3.397","article-title":"Mild cognitive impairment represents early-stage Alzheimer disease","volume":"58","author":"Morris","year":"2001","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib80","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib81","doi-asserted-by":"crossref","first-page":"e33182","DOI":"10.1371\/journal.pone.0033182","article-title":"Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib82","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3174\/ajnr.A1357","article-title":"Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: A meta-analysis","volume":"30","author":"Yuan","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1742-1241.2011.02845.x","article-title":"Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer\u2019s disease in subjects with mild cognitive impairment","volume":"66","author":"Zhang","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib84","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jalz.2014.12.001","article-title":"Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics","volume":"11","author":"Prestia","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib85","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00259-013-2478-8","article-title":"11C-PIB, 18F-FDG and MR imaging in patients with mild cognitive impairment","volume":"40","author":"Bruck","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib86","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1212\/01.WNL.0000147469.18313.3B","article-title":"MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET","volume":"63","author":"Mosconi","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib87","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","article-title":"Impact of molecular imaging on the diagnostic process in a memory clinic","volume":"9","author":"Ossenkoppele","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib88","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.09.005_bib89","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/awq277","article-title":"Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer\u2019s disease","volume":"133","author":"Jack","year":"2010","journal-title":"Brain"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib90","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jalz.2012.09.016","article-title":"Diagnostic accuracy of markers for prodromal Alzheimer\u2019s disease in independent clinical series","volume":"9","author":"Prestia","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"15","key":"10.1053\/j.semnuclmed.2016.09.005_bib91","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","article-title":"Relationships between biomarkers in aging and dementia","volume":"73","author":"Jagust","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib92","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1148\/radiol.12120010","article-title":"Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers","volume":"266","author":"Shaffer","year":"2013","journal-title":"Radiology"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib93","doi-asserted-by":"crossref","first-page":"e66877","DOI":"10.1371\/journal.pone.0066877","article-title":"Diagnosed mild cognitive impairment due to Alzheimer\u2019s disease with PET biomarkers of beta amyloid and neuronal dysfunction","volume":"8","author":"Hatashita","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib94","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neurobiolaging.2013.06.018","article-title":"Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer\u2019s dementia","volume":"35","author":"Trzepacz","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.09.005_bib95","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0b013e3182872830","article-title":"Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease","volume":"80","author":"Prestia","year":"2013","journal-title":"Neurology"},{"issue":"Pt 5","key":"10.1053\/j.semnuclmed.2016.09.005_bib96","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/brain\/awv029","article-title":"Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage","volume":"138","author":"Vos","year":"2015","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib97","unstructured":"Alzheimer\u2019s Association New diagnostic criteria and guidelines for Alzheimer\u2019s disease. 2015."},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib98","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"issue":"20","key":"10.1053\/j.semnuclmed.2016.09.005_bib99","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/exnr.2000.7342","article-title":"Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies","volume":"162","author":"Higuchi","year":"2000","journal-title":"Exp Neurol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.09.005_bib101","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02984489","article-title":"Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies","volume":"18","author":"Ishii","year":"2004","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib102","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/archneur.58.3.505","article-title":"Dementia with Lewy bodies studied with positron emission tomography","volume":"58","author":"Cordery","year":"2001","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000051257","article-title":"Occipital glucose metabolism in dementia with lewy bodies with and without Parkinsonism: A study using positron emission tomography","volume":"12","author":"Imamura","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib104","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1159\/000132084","article-title":"Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations","volume":"25","author":"Perneczky","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.09.005_bib105","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.0000000000000734","article-title":"Dementia with Lewy bodies: Basis of cingulate island sign","volume":"83","author":"Graff-Radford","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib106","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0891988704267468","article-title":"Functional imaging in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"17","author":"Colloby","year":"2004","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib107","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1468-1331.2007.01977.x","article-title":"A comparison of cerebral glucose metabolism in Parkinson\u2019\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies","volume":"14","author":"Yong","year":"2007","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.09.005_bib108","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.neurobiolaging.2011.09.024","article-title":"Multimodality imaging characteristics of dementia with Lewy bodies","volume":"33","author":"Kantarci","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.09.005_bib109","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib110","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib111","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib112","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jagp.2013.03.001","article-title":"Amyloid PET Imaging in Lewy body disorders","volume":"23","author":"Donaghy","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.09.005_bib113","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","article-title":"Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy","volume":"78","author":"Walker","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib114","first-page":"464","article-title":"Frontotemporal dementias","volume":"22","author":"Finger","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"Pt 9","key":"10.1053\/j.semnuclmed.2016.09.005_bib115","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.09.005_bib116","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","article-title":"Advances in understanding the molecular basis of frontotemporal dementia","volume":"8","author":"Rademakers","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib117","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1017\/S1462399409001136","article-title":"The molecular basis of frontotemporal dementia","volume":"11","author":"Neumann","year":"2009","journal-title":"Expert Rev Mol Med"},{"issue":"Pt 10","key":"10.1053\/j.semnuclmed.2016.09.005_bib118","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/brain\/awm177","article-title":"FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer\u2019s disease","volume":"130","author":"Foster","year":"2007","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib119","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1259\/bjr\/97295129","article-title":"Positron emission tomography imaging in dementia","volume":"80","author":"Herholz","year":"2007","journal-title":"Br J Radiol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2016.09.005_bib120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF02988628","article-title":"Clinical application of positron emission tomography for diagnosis of dementia","volume":"16","author":"Ishii","year":"2002","journal-title":"Ann Nucl Med"},{"issue":"Pt 7","key":"10.1053\/j.semnuclmed.2016.09.005_bib121","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/brain\/awr130","article-title":"Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer\u2019s disease","volume":"134","author":"de Souza","year":"2011","journal-title":"Brain"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib122","first-page":"10N","article-title":"GE \u03b2-amyloid agent approved","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib123","first-page":"15N","article-title":"FDA approves 18F-florbetapir PET agent","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib125","unstructured":"Centers for Medicare and Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). 2013."},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib126","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.jalz.2013.06.001","article-title":"Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib127","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib128","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/ene.12325","article-title":"Estimating the burden of early onset dementia; systematic review of disease prevalence","volume":"21","author":"Lambert","year":"2014","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.09.005_bib129","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1532-5415.1999.tb02571.x","article-title":"Clinico-neuropathological correlation of Alzheimer\u2019s disease in a community-based case series","volume":"47","author":"Lim","year":"1999","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib131","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002093-199205000-00004","article-title":"Clinically diagnosed Alzheimer disease: Neuropathologic findings in 650 cases","volume":"6","author":"Mendez","year":"1992","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib132","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1212\/WNL.57.2.226","article-title":"Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study","volume":"57","author":"Petrovitch","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib133","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","article-title":"Biomarker modeling of Alzheimer\u2019s disease","volume":"80","author":"Jack","year":"2013","journal-title":"Neuron"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib134","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain beta-amyloid load approaches a plateau","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib136","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1745-6215-13-56","article-title":"Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): Study protocol for a randomised controlled trial","volume":"13","author":"Thyrian","year":"2012","journal-title":"Trials"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib137","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2014.11.001","article-title":"2014 Update of the Alzheimer\u2019s disease neuroimaging initiative: A review of papers published since its inception","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.09.005_bib138","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1212\/WNL.0000000000001903","article-title":"Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease","volume":"85","author":"Wang","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1053\/j.semnuclmed.2016.09.005_bib139","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","article-title":"The Alzheimer\u2019s Disease Neuroimaging Initiative 2 PET Core: 2015","volume":"11","author":"Jagust","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1053\/j.semnuclmed.2016.09.005_bib140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"issue":"226","key":"10.1053\/j.semnuclmed.2016.09.005_bib141","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/scitranslmed.3007901","article-title":"Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease","volume":"6","author":"Fagan","year":"2014","journal-title":"Sci Transl Med"},{"issue":"47","key":"10.1053\/j.semnuclmed.2016.09.005_bib142","doi-asserted-by":"crossref","first-page":"E4502","DOI":"10.1073\/pnas.1317918110","article-title":"Regional variability of imaging biomarkers in autosomal dominant Alzheimer\u2019s disease","volume":"110","author":"Benzinger","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","article-title":"Apolipoprotein E \u03b54 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease","volume":"34","author":"Fleisher","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.09.005_bib144","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/alzrt213","article-title":"Dominantly Inherited Alzheimer Network: Facilitating research and clinical trials","volume":"5","author":"Moulder","year":"2013","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1053\/j.semnuclmed.2016.09.005_bib145","doi-asserted-by":"crossref","first-page":"e0152082","DOI":"10.1371\/journal.pone.0152082","article-title":"Quantitative amyloid imaging in autosomal dominant Alzheimer\u2032s disease: Results from the DIAN Study Group","volume":"11","author":"Su","year":"2016","journal-title":"PLoS One"},{"issue":"23","key":"10.1053\/j.semnuclmed.2016.09.005_bib146","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1523\/JNEUROSCI.0730-07.2007","article-title":"Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees","volume":"27","author":"Klunk","year":"2007","journal-title":"J Neurosci"},{"issue":"Pt 7","key":"10.1053\/j.semnuclmed.2016.09.005_bib147","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/brain\/awn107","article-title":"PET amyloid ligand 11C-PIB uptake shows predominantly striatal increase in variant Alzheimer\u2019s disease","volume":"131","author":"Koivunen","year":"2008","journal-title":"Brain"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib148","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archneurol.2009.285","article-title":"High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types","volume":"66","author":"Villemagne","year":"2009","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2016.09.005_bib149","first-page":"759","article-title":"Outcomes of Alzheimer\u2019s disease therapy with acetylcholinesterase inhibitors and memantine","volume":"13","author":"Zemek","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1053\/j.semnuclmed.2016.09.005_bib150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch Neurol"},{"issue":"17","key":"10.1053\/j.semnuclmed.2016.09.005_bib151","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1212\/WNL.0000000000000364","article-title":"Clinical trial of an inhibitor of RAGE-A\u03b2 interactions in Alzheimer disease","volume":"82","author":"Galasko","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib152","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib153","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"issue":"15","key":"10.1053\/j.semnuclmed.2016.09.005_bib154","first-page":"1460","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib156","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib157","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"10043","key":"10.1053\/j.semnuclmed.2016.09.005_bib158","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib159","unstructured":"Neurimmune. Interim analysis of phase 1b study of Aducanumab\/BIIB037 to treat Alzheimer\u2019s disease shows reduction in beta amyloid levels and acceptable safety profile. 2014."},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib160","unstructured":"Neurimmune. Neurimmune receives major development milestone upon initiation of global phase 3 studies with aducanumab for early Alzheimer\u2019s disease. 2015."},{"issue":"228","key":"10.1053\/j.semnuclmed.2016.09.005_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: Stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.semnuclmed.2016.09.005_bib162","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-2011-0059","article-title":"Alzheimer\u2019s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments","volume":"26","author":"Reiman","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1053\/j.semnuclmed.2016.09.005_bib163","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrneurol.2015.177","article-title":"CAP\u2014Advancing the evaluation of preclinical Alzheimer disease treatments","volume":"12","author":"Reiman","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib164","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","article-title":"Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial","volume":"169","author":"Mills","year":"2013","journal-title":"Rev Neurol (Paris)"},{"issue":"10","key":"10.1053\/j.semnuclmed.2016.09.005_bib165","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","article-title":"Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer\u2019s disease pathophysiology (SNAP) or Alzheimer\u2019s disease pathology: A longitudinal study","volume":"15","author":"Burnham","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib166","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrneurol.2015.251","article-title":"Suspected non-Alzheimer disease pathophysiology\u2014Concept and controversy","volume":"12","author":"Jack","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib167","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease","volume":"66","author":"Morris","year":"2009","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib168","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1212\/WNL.0000000000001401","article-title":"Spatially distinct atrophy is linked to \u03b2-amyloid and tau in preclinical Alzheimer disease","volume":"84","author":"Wang","year":"2015","journal-title":"Neurology"},{"issue":"20","key":"10.1053\/j.semnuclmed.2016.09.005_bib169","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000000432","article-title":"Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions","volume":"82","author":"Ossenkoppele","year":"2014","journal-title":"Neurology"},{"issue":"12","key":"10.1053\/j.semnuclmed.2016.09.005_bib170","first-page":"1512","article-title":"Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people","volume":"70","author":"Wirth","year":"2013","journal-title":"JAMA Neurol"},{"issue":"13","key":"10.1053\/j.semnuclmed.2016.09.005_bib171","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1523\/JNEUROSCI.4409-12.2013","article-title":"Alzheimer\u2019s disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals","volume":"33","author":"Wirth","year":"2013","journal-title":"J Neurosci"},{"issue":"5","key":"10.1053\/j.semnuclmed.2016.09.005_bib172","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/gps.4173","article-title":"Comparison of imaging biomarkers for Alzheimer\u2019s disease: amyloid imaging with 18F-florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy","volume":"30","author":"Tateno","year":"2015","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"10.1053\/j.semnuclmed.2016.09.005_bib173","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ana.23650","article-title":"Amyloid deposition, hypometabolism, and longitudinal cognitive decline","volume":"72","author":"Landau","year":"2012","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2016.09.005_bib174","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neurobiolaging.2010.03.011","article-title":"Cognition, glucose metabolism and amyloid burden in Alzheimer\u2019s disease","volume":"33","author":"Furst","year":"2012","journal-title":"Neurobiol Aging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299816300782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299816300782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T21:20:13Z","timestamp":1657833613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299816300782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":173,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0001299816300782"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.09.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Amyloid Imaging","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}